CommercialPrior AuthLow impact
08.01.67d, Lurbinectedin (Zepzelca®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
The medical necessity criteria for Lurbinectedin (Zepzelca®), an oncology medication, have been updated for commercial insurance plans. This change affects prior authorization requirements and coverage determinations for this specialized cancer treatment drug.
Action Required
By June 1, 2026: Oncology providers and billing teams must review updated medical necessity criteria for Lurbinectedin (Zepzelca®) prescriptions. Update prior authorization workflows to reflect new criteria requirements. Ensure documentation meets revised standards to avoid claim denials for this specialty oncology medication.